Disease mongering in drug promotion: Do governments have a regulatory role?

PLoS Medicine

Volumn 3, Issue 4, 2006, Pages 461-465

  Mintzes, Barbara ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATOMOXETINE; ATORVASTATIN; BOSENTAN; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ESOMEPRAZOLE; ETANERCEPT; ETHINYLESTRADIOL PLUS LEVONORGESTREL; FLUOXETINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; ITRACONAZOLE; LEXIDRONAM SAMARIUM SM 153; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PAROXETINE; PROSTAGLANDIN E1; PROTON PUMP INHIBITOR; ROFECOXIB; SCOPOLAMINE METHYL BROMIDE; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; TERBINAFINE; UNINDEXED DRUG; VALDECOXIB; VARDENAFIL; VENLAFAXINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTHRITIS; ATTENTION DEFICIT DISORDER; BACTERIAL INFECTION; BONE METASTASIS; BREAST CANCER; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLOSTRIDIUM DIFFICILE; DEMENTIA; DEPRESSION; DRUG INDUSTRY; DRUG MARKETING; ESOPHAGITIS; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; GOVERNMENT REGULATION; HEALTH CARE POLICY; HEALTH HAZARD; HEART INFARCTION; HORMONE SUBSTITUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMPOTENCE; LUNG EMBOLISM; MENOPAUSE; MORBIDITY; ONYCHOMYCOSIS; PEPTIC ULCER; PREMENSTRUAL DYSPHORIC DISORDER; PSORIASIS VULGARIS; PULMONARY HYPERTENSION; REVIEW; SOCIAL PHOBIA; STROKE; ADVERTIZING; ARTICLE; AWARENESS; CHRONIC DISEASE; CONSUMER; DEATH; DRUG LEGISLATION; FEAR; FINANCIAL MANAGEMENT; PUBLIC HEALTH; UNITED STATES;

ADVERTISING AS TOPIC; AWARENESS; CHRONIC DISEASE; CONSUMER PARTICIPATION; DEATH; DRUG INDUSTRY; FEAR; HEALTH POLICY; HORMONE REPLACEMENT THERAPY; HUMANS; LEGISLATION, DRUG; MENOPAUSE; PUBLIC HEALTH; RESEARCH SUPPORT AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33646256301     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0030198     Document Type: Review

References (36)

1. Moynihan R, Heath I, Henry D (2002) Selling sickness: The pharmaceutical industry and disease mongering. BMJ 324: 886-891.
2. World Health Organization (2004) World medicines situation. Geneva: World Health Organization. Available: http://w3.whosea.org/LinkFiles/Reports_World_Medicines_ Situation.pdf. Accessed 7 March 2006.
3. Brown B, Standing Committee on Health (2004) Opening the medicine cabinet: First report on health aspects of prescription drugs. Ottawa (Ontario): House of Commons. Available: http://www.parl.gc.ca/InfocomDoc/Documents/37/3/parlbus/commbus/house/reports/ healrp01-e.htm. Accessed 7 March 2006.
4. Van Egmond-Vettenburg JS, ter Steege H (2001) Marketing plans for medicinal products available on prescription only: The current situation. Health Care Inspectorate. Amsterdam: The Hague. Available: http://healthyskepticism.org/publications/editions/2002/IN04.htm. Accessed 7 March 2006.
5. Parmar H (2005 December) The communication gap: Pharmaceutical direct-to-consumer advertising in Europe. Pharmaceutical Field. Available: http://www.inpharm.com/static/intelligence/pdf/MAG_394184.pdf. Accessed 7 March 2006.
6. Outterson K (2005) Agony in the antipodes: The generic drug provisions of the Australia-USA free trade agreement. J Gen Med 2: 316-326.
7. Gardner D, Mintzes B, Ostry A (2003) Direct-to-consumer prescription drug advertising in Canada: Permission by default? CMAJ 169: 425-427.
8. Berndt ER (2005) To inform or persuade? Direct-to-consumer advertising of prescription drugs. N Engl J Med 352: 325-328.
9. Division of Drug Marketing, Advertising, and Communication; US Food and Drug Administration (2004) Guidance for industry. "Help-seeking" and other disease awareness communications by or on behalf of drug and device firms. Rockville (Maryland): US Food and Drug Administration. Available: http://www.fda.gov/cder/guidance/6019dft.pdf. Accessed 7 March 2006.
10. Jackson T (2003) Regulator spells out rules on disease awareness campaigns. BMJ 326: 1219.
11. Sheldon T (2002) Dutch GPs call for a ban on Novartis products. BMJ 325: 355.
12. 't Jong GW, Stricker BWH, Sturkenboom MCJM (2004) Marketing in the lay media and prescriptions of terbinafine in primary care. BMJ 328: 931.
13. Therapeutics Initiative (2003) Do statins have a role in primary prevention? Ther Lett 48. Available: http://www.ti.ubc.ca/PDF/48.pdf. Accessed 7 March 2006.
14. Quick JD, Hogerzeil HV, Rago L, Reggi V, de Joncheere K (2003) Ensuring ethical drug promotion - Whose responsibility? Lancet 362: 747.
15. Pettigrew P (2005) Minister of health. Letter to Anne Rochon Ford, June 16, 2004. Toronto (Ontario): Women and Health Protection. Available: http://www.whp-apsf.ca/pdf/Pfizer_adRresponse.pdf. Accessed 7 March 2006.
16. Lenzer J (2004) US consumer body calls for review of cholesterol guidelines. BMJ 329: 759.
17. Pfizer (2006) Form 10-Q for Pfizer Inc. Quarterly report. May 6, 2005. Item 2. Management's discussion and analysis of financial condition and results of operations. New York: Pfizer. Available: http://biz.yahoo.com/e/050506/pfe10-q.html. Accessed 7 March 2006.
18. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288: 321-333.
19. Fem 7 (1998-1999) Menopausal complaints - Estrogen deficiency. Darmstadt (Germany): Merck KGaA. Available: http://www.fem7. com/estrogen.htm. Accessed 7 March 2007.
20. The Society of Obstetricians and Gynaecologists of Canada (2006) The journalist's menopause handbook. Ottawa (Ontario): The Society of Obstetricians and Gynaecologists of Canada. Available: http://www.sogc.org/media/pdf/advisories/Menopause-journalists-guide_e.pdf. Accessed 7 March 2006.
21. Mamdani M, Juurlink DN, Kopp A, Naglie G, Austin PC, et al. (2004) Gastrointestinal bleeding after the introduction of Cox-2 inhibitors: Ecological study. BMJ 328: 1415-1416.
22. Bashford JNR, Norwood J, Chapman SR (1998) Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database. BMJ 317: 452-456.
23. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D (2004) Risk of clostridium difficile among hospital inpatients prescribed proton pump inhibitors: Cohort and case-control studies. CMAJ 171: 33-38.
24. Class S (2002) Pharma overview. Chem Eng News 80: 39-49. Available: http://pubs.acs.org/cen/coverstory/8048/8048pharmaceutical. html. Accessed 7 March 2006.
25. European Agency for the Evaluation of Medicinal Products [EMEA], Committee for Proprietary Medicinal Products [CPMP] (2003) Summary information on referral opinion following arbitration pursuant to article 30 of council directive 2001/83/EC for Prozac and associated names. London: EMEA. Available: http://www.emea.eu.int/pdfs/human/referral/326303en.pdf. Accessed 7 March 2006.
26. National Prescribing Service (2004) Sertraline (Zoloft), fluoxetine (Lovan, Prozac) for premenstrual dysphoric disorder. Surry Hills (New South Wales): National Prescribing Service. Available: http://www.npsradar.org.au/site.php?page=1&content=/npsradar/content/ sertraline.html#Reason_for_PBS_listing. Accessed 7 March 2006.
27. Stockbridge LL (2002) Untitled letter to G Brophy, Director U.S. Regulatory Affairs, Eli Lilly. Rockville (Maryland): US Food and Drug Administration. Available: http://www.fda.gov/cder/warn/nov2000/dd9523.pdf. Accessed 7 March 2006.
28. Wittchen HU, Becker E, Lieb R, Krause P (2002) Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 32: 119-132.
29. Moynihan R, Cassels A (2005) Selling sickness: How the worlds biggest pharmaceutical companies are turning us all into patients. New York: Nation Books. 254 p.
30. US Food and Drug Administration (2005) Warning letters and untitled letters to pharmaceutical companies. Rockville (Maryland): US Food and Drug Administration. Available: http://www.fda.gov/cder/warn. Accessed 7 March 2006.
31. Lacasse J, Leo J (2005) Serotonin and depression: A disconnect between the advertisements and the scientific literature. PLoS Med 2: e392. DOI: 10.1371/journal.pmed.0020392
32. O'Brien C (2003 October 5) Drug firm to drop non-addiction claim. Irish Times.
33. Kravitz RL, Epstein RM, Feldman MD, Franz CE, Azari R, et al. (2005) Influence of patients' requests for direct-to-consumer advertised antidepressants: A randomised controlled trial. JAMA 293: 1995-2002.
34. European Commission (2003) Community code relating to medicinal products for human use. Brussels: European Commission. Available: http://europa.eu.int/scadplus/leg/en/lvb/l21230.htm. Accessed 7 March 2006.
35. Department of Justice [Canada]. Food and Drugs Act. Chapter F-27. Ottawa (Ontario). Available: http://laws.justice.gc.ca/en/ F-27/191368.html. Accessed 7 March 2006
36. World Health Organization (1988) Ethical criteria for medicinal drug promotion. Geneva: World Health Organization. Available: http://mednet2.who.int/tbs/promo/whozip08e.pdf. Accessed 7 March 2006.